



or a pharmaceutically acceptable salt thereof, wherein:

R<sup>1</sup> is selected from the group consisting of hydrogen, halo, C<sub>1</sub>-C<sub>5</sub> alkyl and C<sub>1</sub>-C<sub>5</sub> alkyl substituted by alkoxy or one or more halo;

R<sup>2</sup> is selected from the group consisting of hydrogen, halo, C<sub>1</sub>-C<sub>5</sub> alkyl and C<sub>1</sub>-C<sub>5</sub> alkyl substituted by alkoxy or one or more halo;

R<sup>3</sup> is C<sub>1</sub>-C<sub>5</sub> alkyl or C<sub>1</sub>-C<sub>5</sub> alkyl substituted by alkoxy or one or more halo.

Please insert therefor:



or a pharmaceutically acceptable salt thereof, wherein:


$R^1$  is selected from the group consisting of hydrogen, halo,  $C_1$ - $C_3$  alkyl and  $C_1$ - $C_3$  alkyl substituted by alkoxy or one or more halo;

$R^2$  is selected from the group consisting of hydrogen, halo,  $C_1$ - $C_3$  alkyl and  $C_1$ - $C_3$  alkyl substituted by alkoxy or one or more halo;

$R^3$  is  $C_1$ - $C_3$  alkyl or  $C_1$ - $C_3$  alkyl substituted by alkoxy or one or more halo.

**Page 4, third paragraph (lines 11-18), to page 5, first paragraph (lines 1-4), please delete (replace):**

In an embodiment represented by Formula I, the invention relates to:



or a pharmaceutically acceptable salt thereof, wherein:


$R^1$  is selected from the group consisting of hydrogen, halo,  $C_1$ - $C_3$  alkyl and  $C_1$ - $C_3$  alkyl substituted by alkoxy or one or more halo;

$R^2$  is selected from the group consisting of hydrogen, halo,  $C_1$ - $C_3$  alkyl and  $C_1$ - $C_3$  alkyl substituted by alkoxy or one or more halo;

$R^3$  is  $C_1$ - $C_3$  alkyl or  $C_1$ - $C_3$  alkyl substituted by alkoxy or one or more halo.

**And insert therefor:**

In an embodiment represented by Formula I, the invention relates to:



I

or a pharmaceutically acceptable salt thereof, wherein:


R<sup>1</sup> is selected from the group consisting of hydrogen, halo, C<sub>1</sub>-C<sub>5</sub> alkyl and C<sub>1</sub>-C<sub>5</sub> alkyl substituted by alkoxy or one or more halo;

R<sup>2</sup> is selected from the group consisting of hydrogen, halo, C<sub>1</sub>-C<sub>5</sub> alkyl and C<sub>1</sub>-C<sub>5</sub> alkyl substituted by alkoxy or one or more halo;

R<sup>3</sup> is C<sub>1</sub>-C<sub>5</sub> alkyl or C<sub>1</sub>-C<sub>5</sub> alkyl substituted by alkoxy or one or more halo.

**Page 5, fourth paragraph (lines 12-23) , please delete (replace):**

In an embodiment represented by Formula III, the invention relates to:



III

or a pharmaceutically acceptable salt thereof, wherein:


R<sup>1</sup> is selected from the group consisting of hydrogen, halo, C<sub>1</sub>-C<sub>5</sub> alkyl and C<sub>1</sub>-C<sub>5</sub> alkyl substituted by alkoxy or one or more halo;

R<sup>2</sup> is selected from the group consisting of hydrogen, halo, C<sub>1</sub>-C<sub>5</sub> alkyl and C<sub>1</sub>-C<sub>5</sub> alkyl substituted by alkoxy or one or more halo;

R<sup>3</sup> is C<sub>1</sub>-C<sub>5</sub> alkyl or C<sub>1</sub>-C<sub>5</sub> alkyl substituted by alkoxy or one or more halo.

And insert therefor:

In an embodiment represented by Formula III, the invention relates to:



III

or a pharmaceutically acceptable salt thereof, wherein:


R<sup>1</sup> is selected from the group consisting of hydrogen, halo, C<sub>1</sub>-C<sub>5</sub> alkyl and C<sub>1</sub>-C<sub>5</sub> alkyl substituted by alkoxy or one or more halo;

R<sup>2</sup> is selected from the group consisting of hydrogen, halo, C<sub>1</sub>-C<sub>5</sub> alkyl and C<sub>1</sub>-C<sub>5</sub> alkyl substituted by alkoxy or one or more halo;

R<sup>3</sup> is C<sub>1</sub>-C<sub>5</sub> alkyl or C<sub>1</sub>-C<sub>5</sub> alkyl substituted by alkoxy or one or more halo.

Page 6, second paragraph (lines 7-17), please delete (replace):

In an embodiment represented by Formula V, the invention relates to:



V

or a pharmaceutically acceptable salt thereof, wherein:


$R^1$  is selected from the group consisting of hydrogen, halo,  $C_1$ - $C_3$  alkyl and  $C_1$ - $C_5$  alkyl substituted by alkoxy or one or more halo;

$R^2$  is selected from the group consisting of hydrogen, halo,  $C_1$ - $C_3$  alkyl and  $C_1$ - $C_5$  alkyl substituted by alkoxy or one or more halo;

$R^3$  is  $C_1$ - $C_5$  alkyl or  $C_1$ - $C_5$  alkyl substituted by alkoxy or one or more halo.

**And insert therefor:**

In an embodiment represented by Formula V, the invention relates to:



V

or a pharmaceutically acceptable salt thereof, wherein:


$R^1$  is selected from the group consisting of hydrogen, halo,  $C_1$ - $C_3$  alkyl and  $C_1$ - $C_5$  alkyl substituted by alkoxy or one or more halo;

$R^2$  is selected from the group consisting of hydrogen, halo,  $C_1$ - $C_3$  alkyl and  $C_1$ - $C_5$  alkyl substituted by alkoxy or one or more halo;

$R^3$  is  $C_1$ - $C_5$  alkyl or  $C_1$ - $C_5$  alkyl substituted by alkoxy or one or more halo.

**Page 17, last paragraph (line 30), to page 18, first paragraph (lines 1-10), please delete (replace):**

In an embodiment represented by Formula I, the invention relates to:



I

or a pharmaceutically acceptable salt thereof, wherein:


$R^1$  is selected from the group consisting of hydrogen, halo,  $C_1$ - $C_5$  alkyl and  $C_1$ - $C_5$  alkyl substituted by alkoxy or one or more halo;

$R^2$  is selected from the group consisting of hydrogen, halo,  $C_1$ - $C_5$  alkyl and  $C_1$ - $C_5$  alkyl substituted by alkoxy or one or more halo;

$R^3$  is  $C_1$ - $C_5$  alkyl or  $C_1$ - $C_5$  alkyl substituted by alkoxy or one or more halo.

**And insert therefor:**

In an embodiment represented by Formula I, the invention relates to:



I

or a pharmaceutically acceptable salt thereof, wherein:


$R^1$  is selected from the group consisting of hydrogen, halo,  $C_1$ - $C_5$  alkyl and  $C_1$ - $C_5$  alkyl substituted by alkoxy or one or more halo;

$R^2$  is selected from the group consisting of hydrogen, halo,  $C_1$ - $C_5$  alkyl and  $C_1$ - $C_5$  alkyl substituted by alkoxy or one or more halo;

$R^3$  is  $C_1$ - $C_5$  alkyl or  $C_1$ - $C_5$  alkyl substituted by alkoxy or one or more halo.

Page 21, ninth paragraph (lines 19-27), to page 22, first paragraph (lines 1-3), please delete (replace):

In an embodiment represented by Formula III, the invention relates to:



III

or a pharmaceutically acceptable salt thereof, wherein:


R<sup>1</sup> is selected from the group consisting of hydrogen, halo, C<sub>1</sub>-C<sub>5</sub> alkyl and C<sub>1</sub>-C<sub>5</sub> alkyl substituted by alkoxy or one or more halo;

R<sup>2</sup> is selected from the group consisting of hydrogen, halo, C<sub>1</sub>-C<sub>5</sub> alkyl and C<sub>1</sub>-C<sub>5</sub> alkyl substituted by alkoxy or one or more halo;

R<sup>3</sup> is C<sub>1</sub>-C<sub>5</sub> alkyl or C<sub>1</sub>-C<sub>5</sub> alkyl substituted by alkoxy or one or more halo.

**And insert therefor:**

In an embodiment represented by Formula III, the invention relates to:



III

or a pharmaceutically acceptable salt thereof, wherein:


$R^1$  is selected from the group consisting of hydrogen, halo,  $C_1$ - $C_5$  alkyl and  $C_1$ - $C_5$  alkyl substituted by alkoxy or one or more halo;

$R^2$  is selected from the group consisting of hydrogen, halo,  $C_1$ - $C_5$  alkyl and  $C_1$ - $C_5$  alkyl substituted by alkoxy or one or more halo;

$R^3$  is  $C_1$ - $C_5$  alkyl or  $C_1$ - $C_5$  alkyl substituted by alkoxy or one or more halo.

**Page 25, fourth paragraph (lines 7-18), please delete (replace):**

In an embodiment represented by Formula V, the invention relates to:



V

or a pharmaceutically acceptable salt thereof, wherein:

$R^1$  is selected from the group consisting of hydrogen, halo,  $C_1$ - $C_5$  alkyl and  $C_1$ - $C_5$  alkyl substituted by alkoxy or one or more halo;

$R^2$  is selected from the group consisting of hydrogen, halo,  $C_1$ - $C_5$  alkyl and  $C_1$ - $C_5$  alkyl substituted by alkoxy or one or more halo;

$R^3$  is  $C_1$ - $C_5$  alkyl or  $C_1$ - $C_5$  alkyl substituted by alkoxy or one or more halo.

**And insert therefor:**

In an embodiment represented by Formula V, the invention relates to: